Shanghai Henlius Biotech, Inc. (HKG:2696)
71.70
+5.70 (8.64%)
At close: Mar 27, 2026
Shanghai Henlius Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 772.21 | 772.96 | 987.67 | 680.48 | 707.33 |
Short-Term Investments | 71.04 | 40.77 | 21.7 | 31.4 | 34.99 |
Cash & Short-Term Investments | 843.25 | 813.73 | 1,009 | 711.87 | 742.32 |
Cash Growth | 3.63% | -19.38% | 41.79% | -4.10% | -34.79% |
Accounts Receivable | 1,833 | 901.36 | 730.25 | 455.51 | 295.74 |
Other Receivables | - | - | - | 160.19 | - |
Receivables | 1,833 | 901.36 | 730.25 | 615.7 | 295.74 |
Inventory | 612.41 | 728.27 | 757.36 | 757.31 | 420.11 |
Other Current Assets | 197.11 | 68.17 | 179.07 | 106.66 | 188.99 |
Total Current Assets | 3,486 | 2,512 | 2,676 | 2,192 | 1,647 |
Property, Plant & Equipment | 2,581 | 2,700 | 2,653 | 2,230 | 1,667 |
Other Intangible Assets | 6,162 | 3,696 | 3,261 | 2,703 | 1,919 |
Long-Term Deferred Charges | 71.52 | 1,659 | 1,250 | 1,629 | 1,716 |
Other Long-Term Assets | 59.81 | 30.34 | 64.16 | 170.61 | 223.67 |
Total Assets | 12,361 | 10,598 | 9,904 | 8,924 | 7,173 |
Accounts Payable | 831.01 | 729.1 | 544.82 | 713.55 | 383.47 |
Accrued Expenses | - | 921.37 | 975.85 | 832.73 | 417.78 |
Short-Term Debt | - | 2,064 | 2,250 | 1,839 | 1,351 |
Current Portion of Long-Term Debt | 2,247 | 430.62 | 463.58 | 601.62 | 145.64 |
Current Portion of Leases | - | 64.98 | 86.96 | 81.45 | 74.19 |
Current Income Taxes Payable | 51.17 | 115.92 | 83.14 | 20.78 | 21.64 |
Current Unearned Revenue | 518.12 | 444.03 | 466.88 | 322.42 | 138.3 |
Other Current Liabilities | 1,294 | 262.06 | 196.37 | 589.94 | 427.86 |
Total Current Liabilities | 4,941 | 5,032 | 5,067 | 5,002 | 2,960 |
Long-Term Debt | 1,350 | 951.27 | 1,106 | 975.29 | 833.7 |
Long-Term Leases | - | 137.4 | 186.46 | 179.65 | 218.56 |
Long-Term Unearned Revenue | 1,921 | 1,314 | 1,179 | 839.09 | 809.68 |
Other Long-Term Liabilities | 188.88 | 149.27 | 172.07 | 292.37 | 54.43 |
Total Liabilities | 8,401 | 7,584 | 7,711 | 7,288 | 4,876 |
Common Stock | 543.5 | 543.5 | 543.5 | 543.5 | 543.5 |
Additional Paid-In Capital | - | 6,069 | 6,069 | 6,052 | 6,010 |
Retained Earnings | - | -3,104 | -3,924 | -4,470 | -3,775 |
Comprehensive Income & Other | 3,417 | -495.26 | -496.11 | -488.43 | -481.1 |
Total Common Equity | 3,960 | 3,014 | 2,192 | 1,636 | 2,297 |
Shareholders' Equity | 3,960 | 3,014 | 2,192 | 1,636 | 2,297 |
Total Liabilities & Equity | 12,361 | 10,598 | 9,904 | 8,924 | 7,173 |
Total Debt | 3,597 | 3,648 | 4,093 | 3,677 | 2,623 |
Net Cash (Debt) | -2,754 | -2,834 | -3,084 | -2,965 | -1,881 |
Net Cash Per Share | -5.04 | -5.22 | -5.68 | -5.47 | -3.49 |
Filing Date Shares Outstanding | 543.49 | 543.49 | 543.49 | 543.49 | 543.49 |
Total Common Shares Outstanding | 543.49 | 543.49 | 543.49 | 543.49 | 543.49 |
Working Capital | -1,455 | -2,520 | -2,391 | -2,810 | -1,313 |
Book Value Per Share | 7.29 | 5.54 | 4.03 | 3.01 | 4.23 |
Tangible Book Value | -2,202 | -682.42 | -1,068 | -1,067 | 377.41 |
Tangible Book Value Per Share | -4.05 | -1.26 | -1.97 | -1.96 | 0.69 |
Buildings | - | 767.01 | 629.26 | -12,931 | - |
Machinery | - | 1,417 | 1,047 | 11,358 | 859.43 |
Construction In Progress | - | 584.24 | 816.16 | 1,003 | 399.69 |
Leasehold Improvements | - | 360.25 | 346.79 | 2,840 | 295.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.